Enlivex Therapeutics Ltd. (ENLV) Key Metrics
ENLV valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.1M
- Enterprise value
- $6.2M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.41
ENLV key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsENLV returns How much profit the business earns on the capital it uses.
ENLV financial health Debt, liquidity and how easily interest is covered.
ENLV efficiency & capital use Working capital cycle and where the cash goes.
ENLV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ENLV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ENLV key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $10.54 | $17.55 | $40.50 | $59.07 | $93.75 | $126.45 | $125.86 | $92.88 | $274.32 | $624.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 126.2% | −55.9% | −66.9% | −43.8% | −24.0% | −50.6% | −89.4% | −65.9% | −100.2% | −120.3% |
| Return on invested capital (ROIC) | −1.2% | −569.5% | −304.8% | −222.0% | −441.8% | — | — | — | — | — |
| Return on assets (ROA) | 104.9% | −46.5% | −55.6% | −38.2% | −21.4% | −40.8% | −65.6% | −57.9% | −83.4% | −102.9% |
| Return on tangible assets | 70.8% | −54.2% | −78.9% | −45.9% | −15.2% | −29.3% | −54.7% | −38.4% | −164.1% | −150.7% |
| Free cash flow margin | — | — | — | — | — | −528.2% | — | — | — | — |
| Income quality (OCF / net income) | −0.01 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $641,000 | $534,000 | $1.0M | $4.8M | $6.0M | $203,000 | $123,000 | — | — | — |
| Cash & short-term investments | $5.9M | $23.6M | $27.3M | $50.2M | $84.1M | $35.7M | $12.0M | $9.8M | $3.5M | $9.9M |
| Net debt | −$5.2M | −$23.1M | −$26.3M | −$45.4M | −$78.1M | −$35.5M | −$11.9M | −$9.8M | −$3.5M | −$9.9M |
| Debt / equity | 0.00 | 0.02 | 0.03 | 0.09 | 0.07 | 0.01 | 0.01 | — | — | — |
| Debt / assets | 0.00 | 0.02 | 0.03 | 0.07 | 0.06 | 0.01 | 0.01 | — | — | — |
| Current ratio | 193.24 | 6.84 | 5.57 | 7.92 | 18.32 | 8.72 | 2.75 | 9.09 | 7.87 | 5.46 |
| Quick ratio | 193.24 | 6.84 | 5.61 | 7.74 | 20.91 | 15.86 | 2.50 | 9.09 | 7.87 | 5.46 |
| Interest coverage | — | — | — | -4.9 | -58.8 | — | — | — | — | — |
| Working capital | $1.73B | $22.2M | $27.7M | $45.7M | $81.7M | $33.7M | $10.4M | $9.1M | $3.2M | $8.6M |
| Invested capital | $1.93B | $514,000 | $3.8M | $11.4M | $6.9M | −$17,000 | −$603,000 | −$70,000 | −$364,000 | −$1.2M |
| Tangible asset value | $1.35B | $23.6M | $30.1M | $56.8M | $85.0M | $35.5M | $10.9M | $9.7M | $3.2M | $8.7M |
| Net current asset value | $1.35B | $21.9M | $27.0M | $41.5M | $76.3M | $33.2M | $10.1M | $8.9M | $3.2M | $8.6M |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | — | $0 |
| Capex / revenue | — | — | — | — | — | 44.8% | — | — | — | — |
| Capex / depreciation | 0.20 | 0.19 | 0.28 | 10.45 | 2.98 | 3.56 | 0.94 | 3.81 | 0.17 | 0.72 |
| Stock-based compensation / revenue | — | — | — | — | — | 29.4% | — | — | — | — |
| R&D / revenue | — | — | — | — | — | 267.3% | — | — | — | — |
| SG&A / revenue | — | — | — | — | — | 158.2% | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 292.2 | — | — | — | — |
| Days of inventory on hand | — | — | 207.2 | -2,589.8 | -14,506.7 | -18,950.6 | 1,843.4 | — | — | — |
| Days payables outstanding | 2,539.1 | 548.5 | 606.5 | 663.8 | 448.2 | 497.1 | 300.5 | 289.6 | 775.6 | 10,541.2 |
| Cash conversion cycle (days) | — | — | — | — | — | -19,155.5 | — | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.14 | 0.67 | 0.60 | 0.55 | 0.81 | 0.73 | 1.21 | 1.26 | 0.47 | 0.03 |
| Inventory turnover | — | — | — | — | — | — | 0.20 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $768,500 | $765,500 | $438,000 | $867,000 | $1.2M | $1.8M | $1.3M | $120,500 | $40,000 | $98,500 |
| Average payables | $2.3M | $819,000 | $1.4M | $1.4M | $670,500 | $389,500 | $244,500 | $96,000 | $25,500 | $722,000 |
| Average inventory | — | — | $474,000 | −$5.5M | −$21.7M | −$14.8M | $1.5M | — | — | — |
| Intangibles / total assets | 25.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% | 0.0% | 0.0% | 0.0% |
Computed from ENLV's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ENLV valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. Enlivex Therapeutics earned a return on equity of 126.2% and a return on invested capital of −1.2% in fiscal 2025. It ended the year with $0.6 million of debt and $5.9 million in cash and short-term investments, a net cash position of $5.2 million.
See the ENLV income statement, the ENLV chart for price history, or the ENLV stock overview for the latest quote and news.
ENLV key metrics FAQ
What is Enlivex Therapeutics's P/E ratio?
Enlivex Therapeutics's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is Enlivex Therapeutics's return on equity?
Enlivex Therapeutics's return on equity (ROE) was 126.2% in fiscal 2025: net income of $1.2 billion on average shareholders' equity of $979.3 million.
What is Enlivex Therapeutics's ROIC?
Enlivex Therapeutics's return on invested capital was −1.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Enlivex Therapeutics have?
Enlivex Therapeutics had total debt of $0.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Enlivex Therapeutics's current ratio?
Enlivex Therapeutics's current ratio was 193.24 at the end of fiscal 2025: current assets were 193.24 times current liabilities.